Vaginal Inserts for Localized Estradiol Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Postmenopausal women often suffer from vulvovaginal atrophy and female sexual dysfunction due to decreased estrogenization, which existing oral estrogen-based treatments may not effectively address, and these conditions can lead to increased vaginal pH, infections, and interference with sexual activity.
Innovation Solution
The development of vaginal inserts comprising a therapeutically effective amount of solubilized estradiol combined with solubilizing agents such as C2-C5 fatty acids, glycol esters, or polyethylene glycol mono- or di-esters, which are encapsulated in soft gelatin capsules for localized delivery to the vaginal tissue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If oral estrogen-based pharmaceutical drug products are used, then systemic estrogen levels are increased, but local vaginal tissue estrogenization is insufficient and systemic side effects occur
Solution Approach 1:
The patent applies local quality by formulating a vaginal insert that delivers estrogen locally to vaginal tissue. The insert contains estrogen combined with solubilizing agents (such as poloxamers, polysorbates, or fatty acids) that enable the hormone to be released directly at the site of need, achieving high local concentration without requiring systemic circulation. This resolves the contradiction by providing sufficient estrogen to vaginal tissue while avoiding the systemic side effects associated with oral administration.
Solution Approach 2:
The patent uses solubilizing agents as intermediaries to facilitate estrogen delivery. These agents (including poloxamers, polysorbates, and fatty acids) act as mediators that solubilize the estrogen hormone and enable its release from the insert into the vaginal tissue. This intermediary system allows for effective local delivery without requiring oral administration, thereby avoiding systemic side effects while maintaining therapeutic effectiveness.
2Quantity of substance
If solubilizing agents are used to dissolve estradiol, then solubility and localized delivery are improved, but formulation complexity increases
Solution Approach 1:
The patent applies parameter changes by selecting solubilizing agents with specific properties (such as HLB values, molecular weights, and chemical structures) that optimize estrogen solubility and release characteristics. By carefully controlling these parameters and using standardized formulations with well-defined compositions, the patent achieves high solubility while managing formulation complexity through systematic selection criteria rather than ad hoc approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vaginal inserts provide effective relief for vulvovaginal atrophy and female sexual dysfunction by maintaining a localized therapeutic effect, reducing symptoms like vaginal dryness and pain, and improving estrogen levels in the vaginal tissue without systemic side effects.
Implementation Method 1
pharmaceutical compositions comprising solubilized estradiol
Data Source
AI summary
This disclosure provides pharmaceutical compositions for delivering estradiol to a subject in need thereof, as well as methods of administering the compositions, and methods of using them.